Summer Sale
50% off Premium Yearly
NYSEARCA:XBI
Spdr S&P Biotech Etf (XBI)
Financials 
Technical Analysis 
Aug 22, 2026, 12:00 amThis summary was created by AI, based on 7 opinions in the last 12 months.
The Spdr S&P Biotech ETF (XBI) has garnered a range of expert opinions recently, reflecting the current dynamics in the biotech sector. Some experts express caution, noting that XBI has underperformed the healthcare sector following a poor performance from March 2023 until summer, while others highlight a recent resurgence in biotech performance, suggesting that the sector is beginning to recover. The ETF's equal weight methodology is positively viewed for its ability to spread volatility, making it a compelling option for capturing growth in early and mid-stage biotech. The potential for explosive growth is emphasized, particularly as advancements in AI are accelerating drug discovery processes, signaling opportunities for substantial upside. However, there is mention of looming risks associated with macroeconomic factors like Federal Reserve policies, which could influence XBI's short-term performance, and thoughts on the IPO market's lack of action, which investors see as supportive for the ETF.
The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.
John ZechnerThis is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.
Cameron Hurst
Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
